An executive director of translational oncology at a major pharma company speaks to how they currently see investments in the precision medicine / oncology space unfolding now and in the next 3 – 5 years. In addition to being a translational lead, they are a diagnostic lead for multiple cancer indications, as well as in the rare disease space. Their company currently invests the most in genomics and liquid biopsy, clinical trial operations, and companion diagnostics. These areas have clear returns in the form of supporting drug development and finding novel treatment targets. They also view supply chain investments as being a top source of ROI, though not holding as significant of an investment share. Trends such as increasing diagnostic regulations(e.g., IVDR), emerging therapeutic modalities, and decentralized care and monitoring have potential to alter spending decisions. Increasing regulation is a pain point in this expert’s opinion, as there is a lack of clarity in how regulations will define the utility of some technologies, for instance, liquid biopsy to stratify patients.
PDF deck with summarized feedback from stakeholders
Individual PDFs of call transcripts with stakeholders
This package includes both the PDF deck and transcripts, providing a comprehensive understanding of stakeholders' views. You will receive a summarized report in the form of a PDF deck, as well as the full transcript of the discussions.
Individual call transcript of a single stakeholder discussing their views. This option is ideal for those who are interested in a specific stakeholder's perspective and insights on the topic.